- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02855541
Health Effects of Increasing Muscle Activation While Sitting in Office Workers
Aperçu de l'étude
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Colorado
-
Boulder, Colorado, États-Unis, 80309
- University of Colorado Boulder
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Both males and females
- Subjects will need to be 18-55 years old
- Subjects will need to be sitting at least 6 hours/day on 5 days/week
- Subjects will need to be exercising less than 5 hour/week
Exclusion Criteria:
- Females that are pregnant or breast-feeding.
Subjects must be free from any acute or chronic physical condition that would influence the outcome measures of the protocol. Examples include, but are not limited to advanced chronic disease states (chronic kidney, liver, heart, or lung disease), morbid obesity, emphysema, and an inability to use the legs for normal locomotion. Normality will be established on the basis of clinical history, physical exam, and vital signs. Any subject with a history of an uncontrolled metabolic disorder/disease or symptoms of active illness will be excluded from study. Any subject with a history of an uncontrolled metabolic disorder/disease such as diabetes (Type I or Type II) or symptoms of active illness will be excluded from study.
- Subjects will be excluded if they have a fasted blood glucose level >126 mg/dl or a systolic blood pressure >140 mmHg.
- Medical/psychiatric/sleep disorders history: any clinically significant unstable medical or psychological condition within the last year (treated or untreated).
Drug use:
- Use of any medications, including over-the-counter and herbal products, that may affect metabolic function within 1 month prior to the study or need to use any of these medications at any time during the study (self-report by interview). Examples of potential medications that will exclude a subject include: beta-adrenergic blockers, sulfonylureas, biguanides, thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, and dipeptidyl peptidase IV inhibitors. Note, subjects may be tested at a later date.
- Use of any investigational drug within 1 month before the study
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Cycling intervention
Participants will use a small cycling device (DeskCycle) at their workstation for 15 minutes every hour that they are at work.
|
A small cycling ergometer that can fit under a desk at the workplace.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Blood Glucose
Délai: Measured after 4 weeks
|
2-h Post Oral Glucose Tolerance Test Blood Glucose
|
Measured after 4 weeks
|
Maximum Oxygen Consumption
Délai: Measured after 4 weeks
|
Maximum oxygen consumption (VO2max) will be used to determine physical fitness
|
Measured after 4 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
Systolic Blood Pressure
Délai: Measured after 4 weeks
|
Measured after 4 weeks
|
HDL Cholesterol
Délai: Measured after 4 weeks
|
Measured after 4 weeks
|
LDL Cholesterol
Délai: Measured after 4 weeks
|
Measured after 4 weeks
|
Triglycerides
Délai: Measured after 4 weeks
|
Measured after 4 weeks
|
Lean Mass
Délai: Measured after 4 weeks
|
Measured after 4 weeks
|
Fat Mass
Délai: Measured after 4 weeks
|
Measured after 4 weeks
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- UColoradoBoulder
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .